Clinical trial · Interventional
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer
Study of the Combined Therapy of Irreversible Electroporation（IRE） and Nature Killer (NK) Cells for Advanced Pancreatic Cancer
NCT02718859CI-TRIAL-00040573completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficacy of the combined therapy using irreversible electroporation（IRE）and nature killer(NK) cells for advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| irreversible electroporation (IRE ) | Procedure | — | UNRESOLVED |
| NK cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- irreversible electroporation (IRE)
- description
- Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
- interventionNames
- Procedure: irreversible electroporation (IRE )
- type
- EXPERIMENTAL
- label
- IRE & NK cells
- description
- Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
- interventionNames
- Biological: NK cells
- Procedure: irreversible electroporation (IRE )
Primary outcomes (1)
- measure
- Relief degree
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:18-80 2. Diagnosis：advanced and active pancreatic cancer 3. The tumour is measurable 4. Eastern Cooperative Oncology Group(ECOG) score：0\~2；3 but has no relationship with tumour 5. Vital organ function is normal: total bilirubin(TB) \<68μmol/L aspartate aminotransferase(AST)\<90 IU/L Cre\<353μmol/L white blood cell count(WBC)\<9×10\^9/L,when WBC is close to or even greater than 9×10\^9/L，the recommended dose should be halved platelet count(PLT)\>80×10\^9/L Red blood cell specific volume(HCT)\>0.20 Non severe viral or bacterial infection 6. Non pregnant and lactating patients 7. Non allergic reactions to biological products 8. Informed and consent Exclusion Criteria: 1. Patients with cardiac pacemaker 2. Patients with severe cardiac and pulmonary dysfunction 3. Patients that the researchers do not think fit into the group,including patients failed in compliance assessment
References
Publications (0)
Data not yet available
No reference posted for this study.